CN103242364A - 磷酸肌酸钠的制备方法 - Google Patents
磷酸肌酸钠的制备方法 Download PDFInfo
- Publication number
- CN103242364A CN103242364A CN2012105822431A CN201210582243A CN103242364A CN 103242364 A CN103242364 A CN 103242364A CN 2012105822431 A CN2012105822431 A CN 2012105822431A CN 201210582243 A CN201210582243 A CN 201210582243A CN 103242364 A CN103242364 A CN 103242364A
- Authority
- CN
- China
- Prior art keywords
- product
- add
- disodium phosphocreatine
- ethanol
- under
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000011734 sodium Substances 0.000 title claims abstract description 18
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 18
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 title abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 105
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 92
- 239000000047 product Substances 0.000 claims abstract description 80
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 76
- 238000006243 chemical reaction Methods 0.000 claims abstract description 69
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims abstract description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 63
- 239000000706 filtrate Substances 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229940109239 creatinine Drugs 0.000 claims abstract description 38
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 239000012043 crude product Substances 0.000 claims abstract description 20
- 239000012535 impurity Substances 0.000 claims abstract description 16
- 238000010438 heat treatment Methods 0.000 claims abstract description 13
- 239000011347 resin Substances 0.000 claims abstract description 12
- 229920005989 resin Polymers 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 11
- 238000000746 purification Methods 0.000 claims abstract description 6
- RNTXMYSPASRLFT-UHFFFAOYSA-L disodium;2-[[n'-[hydroxy(oxido)phosphoryl]carbamimidoyl]-methylamino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(C)C(N)=NP([O-])([O-])=O RNTXMYSPASRLFT-UHFFFAOYSA-L 0.000 claims description 90
- 238000003756 stirring Methods 0.000 claims description 65
- 239000000243 solution Substances 0.000 claims description 47
- 238000004821 distillation Methods 0.000 claims description 30
- 238000007670 refining Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 239000000758 substrate Substances 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 17
- 238000013019 agitation Methods 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- 238000000967 suction filtration Methods 0.000 claims description 15
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 150000001768 cations Chemical class 0.000 claims description 11
- 238000010899 nucleation Methods 0.000 claims description 11
- 230000006911 nucleation Effects 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 229960003624 creatine Drugs 0.000 claims description 7
- 239000006046 creatine Substances 0.000 claims description 7
- 238000005292 vacuum distillation Methods 0.000 claims description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 5
- 239000000543 intermediate Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000009736 wetting Methods 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 239000002244 precipitate Substances 0.000 abstract description 2
- 239000013067 intermediate product Substances 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 239000005457 ice water Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 40
- 229950007002 phosphocreatine Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- -1 carboxylate salt Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WPGUUPJOAVPZBQ-UHFFFAOYSA-N [Cl].OP(O)(O)=O Chemical compound [Cl].OP(O)(O)=O WPGUUPJOAVPZBQ-UHFFFAOYSA-N 0.000 description 2
- LIFQNEZWKPGTNT-UHFFFAOYSA-N [Na].[Na].NC(=N)N(C)C(C(O)=O)P(O)(O)=O Chemical class [Na].[Na].NC(=N)N(C)C(C(O)=O)P(O)(O)=O LIFQNEZWKPGTNT-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical class CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210582243.1A CN103242364B (zh) | 2012-12-28 | 2012-12-28 | 磷酸肌酸钠的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210582243.1A CN103242364B (zh) | 2012-12-28 | 2012-12-28 | 磷酸肌酸钠的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103242364A true CN103242364A (zh) | 2013-08-14 |
CN103242364B CN103242364B (zh) | 2016-03-23 |
Family
ID=48922268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210582243.1A Active CN103242364B (zh) | 2012-12-28 | 2012-12-28 | 磷酸肌酸钠的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103242364B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103819502A (zh) * | 2014-03-01 | 2014-05-28 | 张家港威胜生物医药有限公司 | 一种制备磷酸肌酸钠的方法 |
CN107501320A (zh) * | 2017-08-03 | 2017-12-22 | 江苏汉斯通药业有限公司 | 磷酸肌酸钠的制备方法 |
CN110294775A (zh) * | 2018-03-23 | 2019-10-01 | 安徽古特生物科技有限公司 | 一种磷酸肌酸钠的纯化方法 |
CN113045603A (zh) * | 2021-03-17 | 2021-06-29 | 山东罗欣药业集团恒欣药业有限公司 | 一种保护心肌药物的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632603A (en) * | 1967-07-06 | 1972-01-04 | Ugine Kuhlmann | Process for the preparation of n2-di-chlorophosphoryl-creatinine |
CN101033237A (zh) * | 2007-03-30 | 2007-09-12 | 上海华拓医药科技发展股份有限公司 | 药用磷酸肌酸二钠盐六水合物及其制备方法 |
CN102702253A (zh) * | 2012-03-23 | 2012-10-03 | 上海龙翔生物医药开发有限公司 | 高含量磷酸肌酸二钠盐的制备方法 |
-
2012
- 2012-12-28 CN CN201210582243.1A patent/CN103242364B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632603A (en) * | 1967-07-06 | 1972-01-04 | Ugine Kuhlmann | Process for the preparation of n2-di-chlorophosphoryl-creatinine |
CN101033237A (zh) * | 2007-03-30 | 2007-09-12 | 上海华拓医药科技发展股份有限公司 | 药用磷酸肌酸二钠盐六水合物及其制备方法 |
CN102702253A (zh) * | 2012-03-23 | 2012-10-03 | 上海龙翔生物医药开发有限公司 | 高含量磷酸肌酸二钠盐的制备方法 |
Non-Patent Citations (1)
Title |
---|
王景辉: "磷酸肌酸二钠盐的制备研究", 《中国优秀博硕士学位论文全文数据库(硕士)工程科技I辑》, 15 September 2004 (2004-09-15), pages 2 - 4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103819502A (zh) * | 2014-03-01 | 2014-05-28 | 张家港威胜生物医药有限公司 | 一种制备磷酸肌酸钠的方法 |
CN107501320A (zh) * | 2017-08-03 | 2017-12-22 | 江苏汉斯通药业有限公司 | 磷酸肌酸钠的制备方法 |
CN110294775A (zh) * | 2018-03-23 | 2019-10-01 | 安徽古特生物科技有限公司 | 一种磷酸肌酸钠的纯化方法 |
CN110294775B (zh) * | 2018-03-23 | 2021-11-26 | 安徽古特生物科技有限公司 | 一种磷酸肌酸钠的纯化方法 |
CN113045603A (zh) * | 2021-03-17 | 2021-06-29 | 山东罗欣药业集团恒欣药业有限公司 | 一种保护心肌药物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103242364B (zh) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101046905B1 (ko) | 염기성 아미노산 염산염 결정의 수득 방법 | |
US10508070B1 (en) | Method for preparing 3-hydroxybutyrate salts | |
CN101508658A (zh) | 牛磺酸的制备方法 | |
CN103242364A (zh) | 磷酸肌酸钠的制备方法 | |
JP2013519657A (ja) | コハク酸を製造する方法 | |
CN107162893A (zh) | (r)‑3‑羟基丁酸及其盐的合成工艺 | |
CN110734465A (zh) | 一种氨基葡萄糖硫酸钾盐的制备方法 | |
CN104045520B (zh) | 一种肌醇及其副产物的制备方法 | |
CN103420881A (zh) | 一种新的药用消旋羟蛋氨酸钙的制备方法 | |
CN104031105A (zh) | 一种胞磷胆碱钠的制备方法 | |
CN101891172A (zh) | 一种食品级磷酸氢二钠的制备方法 | |
CN101492470B (zh) | 磷酸肌酸二钠盐的合成方法 | |
CN103167872A (zh) | 用于生产l-肉碱酒石酸盐的方法 | |
CN112552167A (zh) | 葡萄糖酸钙的制备方法 | |
CN102476822A (zh) | 一种药品级氯化钙的生产工艺 | |
CN101486730A (zh) | 一种磷酸肌酸钠化合物及其合成方法 | |
CN100491337C (zh) | 诱导结晶法制备左旋丝氨酸和右旋丝氨酸的方法 | |
CN110627792A (zh) | 一种己酮可可碱化合物 | |
CN104628766B (zh) | 一种甘油磷酸胆碱的工业制造方法 | |
JP2020509073A (ja) | 2’−フコシルラクトースを結晶化するためのプロセス及び関連組成物 | |
CN107986957A (zh) | 一种山梨酸的制备方法 | |
CN114394892A (zh) | 一种(r)-3-羟基丁酸盐的制备方法 | |
CN114630814A (zh) | 使用水溶剂结晶从水性溶液中回收甲羟戊酸或其盐或内酯的方法及其组合物 | |
CN101844991B (zh) | L-亮氨酸硝酸盐的制备方法 | |
CN112939806B (zh) | 一种卡比多巴的精制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method of preparing creatine phosphate sodium Effective date of registration: 20170905 Granted publication date: 20160323 Pledgee: Bank of China Limited by Share Ltd Kaifeng branch Pledgor: Kaifeng Mingren Pharmaceutical Co., Ltd. Registration number: 2017990000824 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181015 Granted publication date: 20160323 Pledgee: Bank of China Limited by Share Ltd Kaifeng branch Pledgor: Kaifeng Mingren Pharmaceutical Co., Ltd. Registration number: 2017990000824 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method of preparing creatine phosphate sodium Effective date of registration: 20181015 Granted publication date: 20160323 Pledgee: Bank of China Limited by Share Ltd Kaifeng branch Pledgor: Kaifeng Mingren Pharmaceutical Co., Ltd. Registration number: 2018990000959 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191209 Granted publication date: 20160323 Pledgee: Bank of China Limited by Share Ltd Kaifeng branch Pledgor: Kaifeng Mingren Pharmaceutical Co., Ltd. Registration number: 2018990000959 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |